Pharmaceutical Business Intelligence

  • Formulary management
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,927,592

« Back to Dashboard

Which drugs does patent 8,927,592 protect, and when does it expire?

Patent 8,927,592 protects JEVTANA KIT and is included in one NDA. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has thirty-six patent family members in twenty-five countries.

Summary for Patent: 8,927,592

Title:Antitumoral use of cabazitaxel
Abstract: The invention relates to a compound of formula: ##STR00001## which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
Inventor(s): Gupta; Sunil (Chester Springs, PA)
Assignee: Aventis Pharma SA (Antony, FR)
Application Number:13/456,720
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,927,592

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China104784187► Subscribe
China106309452► Subscribe
Colombia6531492► Subscribe
Costa Rica20120204► Subscribe
Dominican RepublicP2012000118► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.